Effects of learning and escitalopram administration on serum BDNF levels, a randomised placebo-controlled trial

Background The brain-derived neurotrophic factor (BDNF) has been implicated in processes essential for neuroplasticity. Learning and serotonin reuptake inhibitors (SSRI) foster neuronal reorganization, a mechanism potentially related to BDNF. This study aims to assess the effects of associative learning and escitalopram on serum BDNF (sBDNF) levels, to gain further knowledge on their dynamic interplay. Methods For three weeks, 37 participants performed one of two associative learning paradigms with either emotional or semantic content daily. During a subsequent three-week period of reversal learning, subjects either received escitalopram (10mg per day) or placebo. Before and after each learning period sBDNF values were assessed. Citalopram plasma levels were measured at the last time point. Linear mixed effects models (LME) and partial Spearman’s rank and Pearson correlations were used for statistical analyses. Results One-way LME resulted in a significant effect of time during the first learning period over both groups (p<0.01). Two-way LME revealed a significant interaction effect of the emotional content learning group and time (p=0.02). Three-way LME (time x reversal learning group x substance) showed no significant effects (all p> 0.05). Furthermore, correlation between citalopram and sBDNF level after three weeks of escitalopram administration exhibit a negative trend (partial Pearson correlation: r=-0.30, p=0.05; partial Spearman’s rank: r=-0.22, p=0.15). Conclusion The results suggest that three weeks of associative emotional content learning affect sBDNF levels, while subsequently assessed citalopram plasma and sBDNF levels tend to correlate negatively. Key Points Emotional learning may affect serum BDNF levels in healthy human subjects Blood levels of citalopram and serum BDNF exhibit a negative correlation

[1]  V. Lessmann,et al.  The physiology of regulated BDNF release , 2020, Cell and Tissue Research.

[2]  G. Kranz,et al.  Repetitive enhancement of serum BDNF subsequent to continuation ECT , 2019, Acta psychiatrica Scandinavica.

[3]  E. Castrén,et al.  Antidepressant drugs act by directly binding to TRKB neurotrophin receptors , 2019, Cell.

[4]  G. Lippi,et al.  Updated overview on interplay between physical exercise, neurotrophins, and cognitive function in humans , 2019, Journal of sport and health science.

[5]  G. Kranz,et al.  Acute and subsequent continuation electroconvulsive therapy elevates serum BDNF levels in patients with major depression , 2019, Brain Stimulation.

[6]  E. Rostrup,et al.  Non-pharmacological modulation of cerebral white matter organization: A systematic review of non-psychiatric and psychiatric studies , 2018, Neuroscience & Biobehavioral Reviews.

[7]  J. Ioannidis,et al.  Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis , 2018, The Lancet.

[8]  Suzanna Becker,et al.  The Effects of Physical Exercise and Cognitive Training on Memory and Neurotrophic Factors , 2017, Journal of Cognitive Neuroscience.

[9]  K Domschke,et al.  Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 , 2017, Pharmacopsychiatry.

[10]  L. Fang,et al.  Meta-analyses of comparative efficacy of antidepressant medications on peripheral BDNF concentration in patients with depression , 2017, PloS one.

[11]  C. Harmer,et al.  SSRI enhances sensitivity to background outcomes and modulates response rates: A randomized double blind study of instrumental action and depression , 2016, Neurobiology of Learning and Memory.

[12]  D. Manahan‐Vaughan,et al.  The requirement of BDNF for hippocampal synaptic plasticity is experience‐dependent , 2016, Hippocampus.

[13]  M. Vinberg,et al.  No effect of escitalopram versus placebo on brain-derived neurotrophic factor in healthy individuals: a randomised trial , 2015, Acta Neuropsychiatrica.

[14]  J. Medina,et al.  Requirement for BDNF in the Reconsolidation of Fear Extinction , 2015, The Journal of Neuroscience.

[15]  Matthias J. Müller,et al.  AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. , 2014, Pharmacopsychiatry.

[16]  I. Izquierdo,et al.  Hippocampal molecular mechanisms involved in the enhancement of fear extinction caused by exposure to novelty , 2014, Proceedings of the National Academy of Sciences.

[17]  Pia Baldinger,et al.  Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET , 2014, NeuroImage.

[18]  Sarah Seton-Rogers,et al.  Therapeutics: Delving deeper into resistance , 2013, Nature Reviews Cancer.

[19]  N. Simon,et al.  Two weeks of pretreatment with escitalopram facilitates extinction learning in healthy individuals , 2013, Human psychopharmacology.

[20]  H. Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders , 2013, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[21]  Mu-ming Poo,et al.  Neurotrophin regulation of neural circuit development and function , 2012, Nature Reviews Neuroscience.

[22]  B. Penninx,et al.  Serum BDNF Concentrations Show Strong Seasonal Variation and Correlations with the Amount of Ambient Sunlight , 2012, PloS one.

[23]  L. Monteggia,et al.  Brain-Derived Neurotrophic Factor and Neuropsychiatric Disorders , 2012, Pharmacological Reviews.

[24]  E. Castrén,et al.  Fear Erasure in Mice Requires Synergy Between Antidepressant Drugs and Extinction Training , 2011, Science.

[25]  Matthias J. Müller,et al.  AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. , 2014, Pharmacopsychiatry.

[26]  F. Chollet,et al.  Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial , 2011, The Lancet Neurology.

[27]  J. Buitelaar,et al.  Determinants of serum brain-derived neurotrophic factor , 2011, Psychoneuroendocrinology.

[28]  E. McAuley,et al.  Brain-Derived Neurotrophic Factor Is Associated with Age-Related Decline in Hippocampal Volume , 2010, The Journal of Neuroscience.

[29]  N. Secher,et al.  Endurance training enhances BDNF release from the human brain. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.

[30]  A. Sartorius,et al.  Correlations and Discrepancies between Serum and Brain Tissue Levels of Neurotrophins after Electroconvulsive Treatment in Rats , 2009, Pharmacopsychiatry.

[31]  Danielle A. Simmons,et al.  Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice , 2009, Proceedings of the National Academy of Sciences.

[32]  Peter A. Bandettini,et al.  Neural substrates of explicit and implicit fear memory , 2009, NeuroImage.

[33]  L. Maffei,et al.  The Antidepressant Fluoxetine Restores Plasticity in the Adult Visual Cortex , 2008, Science.

[34]  H. Brückmann,et al.  Cerebral Differences in Explicit and Implicit Emotional Processing – An fMRI Study , 2007, Neuropsychobiology.

[35]  Daniel L Schacter,et al.  Evidence for a specific role of the anterior hippocampal region in successful associative encoding , 2007, Hippocampus.

[36]  G. Lynch,et al.  Restoration of long-term potentiation in middle-aged hippocampus after induction of brain-derived neurotrophic factor. , 2006, Journal of neurophysiology.

[37]  K. Erlandsson,et al.  Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: a SPECT validation study , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  A. Mørk,et al.  The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels , 2004, Brain Research.

[39]  K. Hashimoto,et al.  Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants , 2003, Biological Psychiatry.

[40]  B R Rosen,et al.  Encoding novel face‐name associations: A functional MRI study , 2001, Human brain mapping.

[41]  G. MacQueen,et al.  Increased hippocampal bdnf immunoreactivity in subjects treated with antidepressant medication , 2001, Biological Psychiatry.

[42]  T. Zetterström,et al.  Manipulations of brain 5-HT levels affect gene expression for BDNF in rat brain , 1999, Neuropharmacology.

[43]  Steven Finkbeiner,et al.  Ca2+ Influx Regulates BDNF Transcription by a CREB Family Transcription Factor-Dependent Mechanism , 1998, Neuron.

[44]  R. Duman,et al.  Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[45]  Aude Oliva,et al.  Establishing a Database for Studying Human Face Photograph Memory , 2012, CogSci.

[46]  J. Frey,et al.  'Synaptic tagging' and 'cross-tagging' and related associative reinforcement processes of functional plasticity as the cellular basis for memory formation. , 2008, Progress in brain research.